Sungkyunkwan University · Medicine
Professor Jong Ho Cho's research lab specializes in thoracic surgery and oncology, with a focus on optimizing surgical outcomes for patients with lung and colorectal cancer. The lab investigates prognostic factors, patient selection criteria, and minimally invasive techniques such as VATS for treating malignant pleural effusion, pulmonary metastases, and early-stage lung cancer. Research also explores biomarkers like PD-L1 and EGFR mutations to guide personalized treatment strategies in non-small cell lung cancer.
Figures are computed from collected data and may differ slightly.
The overall survival and recurrence after pulmonary metastasectomy for CRC is dependent on the number of metastases. Surgical treatment can be offered to patients with three or fewer pulmonary metastases. However, more meticulous patient selection is required to decide whether a surgical approach is feasible in patients with four or more pulmonary metastases.
We identified previous chemotherapy or radiotherapy and poor performance status (ECOG 3 or 4) as significant predictors of OS after VATS talc pleurodesis. These prognostic factors can help surgeons select candidates for VATS pleurodesis for malignant pleural effusion.
PD-L1 expression is associated with disease stage and type of <i>EGFR</i> mutation. PD-L1 positivity might be associated with worse RFS among patients with surgically treated <i>EGFR</i>-mutant NSCLC.
These preliminary results suggest that non-intubated VATS lung biopsy is a safe and feasible option in patients with ILD.
Conditional survival estimates generally increase over time, and the largest improvements were observed for patients with advanced stage. Availability of updated prognosis at various time points allows clinicians to better guide their patients. Our results also imply substantial residual risk of recurrence and sustained excess mortality compared to the general population even after 5 years.
Repositioning of the mediastinum with placement of a saline filled tissue expander for PPS is very effective for the relief of symptoms, with low mortality.
Our findings suggest that individuals with MetS may be at increased risk for esophageal cancer, specifically ESCC. Further studies are needed to establish the relationship between MetS and esophageal cancer.
Bilobectomy is associated with high operative mortality and poor long-term survival after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer. The outcomes of bilobectomy were similar to those of pneumonectomy in terms of overall survival, disease-free survival, and postoperative mortality.
Open papers in the app to read, cite, and organize with AI.
